Atlas Trials

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Clinical trial NCT05169515 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05169515
Sponsor
Hoffmann-La Roche
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Non-Hodgkin Lymphoma
Start date
2022-10-26
Primary completion
2029-08-05
Enrollment
121

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.